---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-041187"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:39:40.085666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Reports Q4 and Full Year 2024 Financial Results and Provides Positive Clinical Updates

## Summary
- Announced positive topline data from Phase 2a RIVER trial in refractory chronic cough, meeting primary endpoint with 57% placebo-adjusted reduction in 24-hour cough frequency.
- Completed enrollment in Phase 2b CORAL trial in IPF patients with chronic cough, topline data expected Q2 2025.
- Sample size re-estimation for CORAL trial reaffirmed original sample size of 160 patients.
- Ended 2024 with $107.6 million cash, expected runway into H2 2026.
- Net loss for 2024 was $47.9 million, compared to $29.1 million in 2023.

## SEC filing metadata
- accession: 0000950170-25-041187
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/0000950170-25-041187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/trvi-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-041187
- JSON: https://secwatch.observer/filing/0000950170-25-041187.json
- Plain text: https://secwatch.observer/filing/0000950170-25-041187.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.